Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bio-Bridge Science Receives Approval for Acquisition of Xinheng Baide.


OAK BROOK, Ill. -- Bio-Bridge Science, Inc. (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
:BGES BGES Belgian Group for Endoscopic Surgery ), a biotechnology company engaged in the commercial development of vaccines for the prevention and treatment of human infectious diseases infectious diseases: see communicable diseases.  announced today that it had received a certificate of approval from the Department of Commerce of Inner Mongolia Inner Mongolia
 Chinese Nei Mongol or Nei-meng-ku

Autonomous region (pop., 2002 est.: 23,790,000), China. Stretching some 1,800 mi (2,900 km) across north-northeastern China, it has an area of 454,600 sq mi (1,177,500 sq km); its capital is Hohhot.
 Autonomous Region of the PRC for approving the acquisition of Xinheng Baide Biotechnology Co. Ltd. BGES has one month to close the transaction, and obtain the new business license. The transaction is expected to close before the end of July.

Dr. Liang Qiao, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of Bio-Bridge said, "We are happy to see the Inner Mongolia government has approved our acquisition of Xinheng Baide. The completion of the acquisition of Xinheng Baide will be a significant first step of our acquisition strategy. We believe Xinheng Baide will provide revenues and complementary products to Bio-Bridge."

This press release contains forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof here·of  
adv.
Of this.


hereof
Adverb

Formal or law of or concerning this

Adv. 1. hereof - of or concerning this; "the twigs hereof are physic"
. Please refer to the Company's SEC filings for additional information.
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 8, 2008
Words:293
Previous Article:BAE Systems Secures $538 Million U.S. Army Contract for Bradley Vehicles and Spare Parts.
Next Article:ConocoPhillips Joins Abu Dhabi National Oil Company in the Development of the Shah Gas Field.
Topics:



Related Articles
Bio-Bridge Science (BGES.OB) Listed On OTC BB.
Bio-Bridge Science (OTCBB: BGES) Presentation at the China Growth Conference Available via Webcast.
BIO-BRIDGE SIGNS DISTRIBUTION PACT WITH XINHUA SURGICAL.
Bio-Bridge Science Inc. Reports Encouraging Data in Pre-Clinical Trials of HIV Vaccine.
Bio-Bridge Science Inc. Featured in Corporate News Section in Investor's Business Daily.
Bio-Bridge-Science Inc. CEO Dr. Liang Qiao Featured in CEOcast Interview.
Bio-Bridge Science Signs a Non-Binding MOU to form a Joint Venture in China.
Bio-Bridge Science Signs an Equity Sale and Purchase Agreement with Xinheng Baide Biotechnology Co. Ltd.
Bio-Bridge Science Announces $2.775 Million Private Placement.
Bio-Bridge Science Completes Acquisition of Xinheng Baide Biotechnology Co. Ltd.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles